Viewpoint
Bypassing the antigen to control rheumatoid arthritis

https://doi.org/10.1016/0167-5699(96)80615-3Get rights and content

Abstract

The lack of an identified causative mechanism is the major limitation in the prevention and treatment of rheumatoid arthritis (RA). Here, Pierre Miossec, Pascale Chomarat and Julie Dechanet analyze the contribution of the T helper (Th)-cell-derived cytokine balance to the disease process and discuss how modulation may lend to clinical benefits despite the lack of a defined target antigen.

References (34)

  • S. Romagnani

    Immunol. Today

    (1991)
  • M. Clerici et al.

    Immunol. Toay

    (1994)
  • A. Kahan et al.

    Am. J. Med.

    (1989)
  • T.G. Wegmann et al.

    Immunol. Today

    (1993)
  • M. Goldman et al.

    Immunol. Today

    (1991)
  • M.I. Elliott et al.

    Lancet

    (1994)
  • R. Kühn et al.

    Cell

    (1993)
  • S.M. Zurawski et al.

    J. Biol. Chem.

    (1995)
  • A.J. Silman et al.

    Br. J. Rheumatol.

    (1993)
  • D.E. Trentham et al.

    Science

    (1993)
  • Y. Iwakura et al.

    Science

    (1991)
  • F.S. Di Giovine et al.

    Arthritis Rheum.

    (1994)
  • T.K. Arasil et al.

    Arthritis Rheum.

    (1991)
  • I.H. Calabrese et al.

    Arthritis. Rheum.

    (1989)
  • A.M. Marmont

    Stem cells

    (1994)
  • J.L. Nelson et al.

    New Engl. J. Med.

    (1993)
  • T.R. Mosmann et al.

    Annu. Rev. Immunol.

    (1989)
  • Cited by (35)

    • Cyclosporine A inhibits IL-15-induced IL-17 production in CD4<sup>+</sup> T cells via down-regulation of PI3K/Akt and NF-κB

      2007, Immunology Letters
      Citation Excerpt :

      We also reported recently that CSA increases production of IL-10 from fibroblast-like synoviocytes, and that this is responsible for inhibiting the production of Th1 and proinflammatory cytokines, including IFN-γ, IL-2, IL-12, and TNF-α [30]. These data lead us to believe that CSA might be an appropriate immunosuppressant in balancing the Th1/Th2 phenotype of memory T cell in RA [31,32]. CSA might be reassessed as a drug acting by a new mechanism because the different receptors produce dissimilar signals via two distinct signaling pathways: (1) antigen-presenting cells contact the TCR, the TCR induces NFAT translocation into the nucleus, and NFAT binds the promoter of the IL-17 gene, causing expression of IL-17 and (2) IL-15 contacts IL-15R, γc of IL-15R mediates stimulation of PI3K/NF-κB, NF-κB translocates into the nucleus, and NF-κB binds the promoter of IL-17 gene, causing expression of IL-17.

    • Biologic agents and immunotherapy in rheumatoid arthritis

      1998, Rheumatic Disease Clinics of North America
    View all citing articles on Scopus
    View full text